Man Group’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$73.1M Buy
134,890
+57,395
+74% +$32.3M 0.12% 197
2026
Q1
$46M Sell
77,495
-1,507
-2% -$751K 0.08% 262
2025
Q4
$38.5M Buy
79,002
+15,953
+25% +$7.43M 0.07% 295
2025
Q3
$26.4M Sell
63,049
-41,887
-40% -$14.1M 0.05% 416
2025
Q2
$30.2M Buy
104,936
+27,433
+35% +$8.2M 0.06% 370
2025
Q1
$23.9M Buy
77,503
+30,780
+66% +$10.5M 0.06% 370
2024
Q4
$16.5M Buy
46,723
+302
+0.7% +$111K 0.04% 513
2024
Q3
$16.6M Sell
46,421
-28,898
-38% -$9.76M 0.04% 516
2024
Q2
$24M Sell
75,319
-31,202
-29% -$8.26M 0.06% 377
2024
Q1
$24.5M Buy
106,521
+71,681
+206% +$16.2M 0.06% 360
2023
Q4
$7.66M Buy
+34,840
New +$8.03M 0.02% 776
2023
Q3
Sell
-15,111
Closed -$3.48M 506
2023
Q2
$3.34M Buy
+15,111
New +$3.35M 0.01% 1029
2023
Q1
Sell
-91,289
Closed -$22.5M 329
2022
Q4
$25.4M Sell
91,289
-32,526
-26% -$8.21M 0.09% 274
2022
Q3
$25.9M Buy
+123,815
New +$27.7M 0.12% 213
2022
Q2
Sell
-67,736
Closed -$13.8M 199
2022
Q1
$12.2M Buy
67,736
+7,026
+12% +$1.34M 0.04% 529
2021
Q4
$13.1M Buy
60,710
+38,600
+175% +$7.58M 0.04% 497
2021
Q3
$4.08M Sell
22,110
-28,991
-57% -$5.71M 0.01% 921
2021
Q2
$9.17M Sell
51,101
-32,856
-39% -$6.26M 0.03% 615
2021
Q1
$14M Sell
83,957
-19,319
-19% -$3.22M 0.06% 334
2020
Q4
$15.7M Buy
103,276
+92,908
+896% +$12.2M 0.07% 278
2020
Q3
$1.05M Sell
10,368
-43,757
-81% -$4.8M ﹤0.01% 1361
2020
Q2
$6.55M Buy
54,125
+51,414
+1,896% +$5.78M 0.03% 545
2020
Q1
$257K Buy
+2,711
New +$258K ﹤0.01% 1419
2019
Q3
Sell
-13,891
Closed -$1.08M 1921
2019
Q2
$1.08M Sell
13,891
-22,330
-62% -$2.09M ﹤0.01% 1504
2019
Q1
$4.25M Sell
36,221
-30,100
-45% -$3.51M 0.02% 1002
2018
Q4
$7.22M Sell
66,321
-9,176
-12% -$1.06M 0.03% 585
2018
Q3
$9.65M Buy
75,497
+28,918
+62% +$3.58M 0.04% 640
2018
Q2
$5.27M Buy
46,579
+12,771
+38% +$1.4M 0.02% 922
2018
Q1
$3.8M Buy
+33,808
New +$4.29M 0.02% 998

Other funds holding UTHR

Man Group's UTHR Position: Q2 2026 in Review

Man Group increased its United Therapeutics (UTHR) stake by 74% in Q2 2026, buying an estimated $32.3M and bringing the position to 134,890 shares worth $73.1M. The position accounts for 0.12% of the portfolio, ranked #197.

Man Group first reported a position in UTHR in Q1 2018 and has held it in 29 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Man Group held 134,890 shares of United Therapeutics worth $73.1M as of Q2 2026.
  • Man Group bought 57,395 United Therapeutics shares in Q2 2026, an estimated $32.3M.
  • United Therapeutics made up 0.12% of Man Group's portfolio in Q2 2026, its #197 holding.
  • Man Group first reported a position in United Therapeutics in Q1 2018 and has held it in 29 quarters since.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.